Supplements

A Treatment Option for Patients with Metastatic Squamous NSCLC Who Progressed After Platinum-Based Chemotherapy

This article is sponsored and developed by Boehringer Ingelheim Pharmaceuticals

 

Read Now

In this supplement to Federal Practitioner ,
Dr. Raja Mudad, MD, discusses:

  • The burden of squamous non-small cell lung cancer among active United States military and veterans
  • Available treatment options for advanced metastatic squamous NSCLC
  • Clinical trial data surrounding a treatment for patients with metastatic squamous NSCLC who have progressed after platinum-based chemotherapy, that can be used as early as second-line

(06/20) PC-US-115598

Read Now

Recommended Reading

Medication-assisted treatment in corrections: A life-saving intervention
Federal Practitioner
USPSTF: Earlier lung cancer screening can double eligibility
Federal Practitioner
Primary prevention statins cut mortality even in the very elderly: VHA study
Federal Practitioner
Hypercalcemia Is of Uncertain Significance in Patients With Advanced Adenocarcinoma of the Prostate
Federal Practitioner
Children rarely transmit SARS-CoV-2 within households
Federal Practitioner
Injection beats pill for long-lasting HIV prevention
Federal Practitioner
AGA releases BRCA risk guidance
Federal Practitioner
More proof that fruit, vegetables, whole grains may stop diabetes
Federal Practitioner
FDA expands Dysport use for cerebral palsy–related spasticity
Federal Practitioner
Hyperglycemia predicts COVID-19 death even without diabetes
Federal Practitioner